Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jun 06, 2023 5:38pm
247 Views
Post# 35483286

RE:RE:RE:RE:Next Catalyst FDA itself - Market itself

RE:RE:RE:RE:Next Catalyst FDA itself - Market itselfWe/ you myself or anyone, have no idea who if anyone has walked away from this present situation.
listening to the KOL presentation, the existing data & analysis is barely a week old.
Matt, was Chrystal clear " don't expect any B.D. Deals the day after KOL".
so, unless you have insider information your " walked away twice" comment, is your opinion.
That is certainly your opinion to have, does not make it true.
All we know 100% is that no B.D. Deal is done YET.
BTW, it's not just myself & others who post on here.
There are 6-7 analysts who follow onc(y)
So far two have reiterated " buy" & one has raised target price as a direct result of the recent news & KOL webinar.
Regarding opinions, please do offer your thoughts.
However unless you have proof. Preface, as such...." I think"...etc.
Yes we know 100% Pfizer has not done a deal, yet. No way of knowing if they have walked away.
Myself ? I think Roche is a likely B.D. Candidate.
They have more to gain from the Goblet outcomes.



<< Previous
Bullboard Posts
Next >>